Formulation, optimization and characterization of Betaxolol hydrochloride proniosomes using 3-2 factorial design
The revolution in nanotechnology has lead to the development of various dosage forms such as vesicular drug delivery and in particular liposomes, niosomes, proniosomes, aquasomes, bilosomes etc. The disad-vantages exhibited by the liposomes, niosomes can be overcome through introduction of proniosomes which are compact liquid crystalline structures and convert to niosomes upon hydration. The investigation is focused on development and optimization of Betaxolol proniosomes using three square factorial design technique with the aid of design expert 11.0 ® trial version. The optimization technique prefers choles-terol and span 60 as independent variables and drug content, vesicular size, and entrapment efficacy as dependent variables. The design generated total 13 formulations among which F10 exhibited 98.1% drug content and 97.3% of entrapment efficacy. In view of other parameters, F10 exhibits 6.5 pH, 3.8 ve-sicular size and follows diffusion mechanism with anomalous drug transport. Hence, the obtained results specify that F10 is optimized and can be opted for commercialization.
2. Nordmann JP, Auzanneau N, Ricard S, Berdeaux G. (2003), Vision related quality of life and topi-cal glaucoma treatment side effects. Health Qual Life Outcomes. 1:75.
3. Linden C, Nuija E, Alm A. (1997), Effects on IOP restoration and blood-aqueous barrier after long term treatment with latanoprost in open angle glaucoma and ocular hypertension. Br J Oph-thalmol. 81:370–372
4. Gurrapu A, Jukanti R, Bobbala SR, Swetha K, Jee-vana JB (2011), Improved oral delivery of valsar-tan from maltodextrin based proniosome pow-der. Adv Powder Technol 23: 583-590
5. Mokhtar M, Sammour OA, Hammad MA, Megrab NA (2008) Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared form proniosome. Int J Pharm 361: 104-111.
6. Alam MI, Baboota S (2010) Pharmacodynamic evaluation of proniosomes transdermal thera-peutic gel containing Celecoxib. Sci Asia 36: 305-311.
7. Mahmoud M, Omaima AS, Mohammed AH, Nagia AM (2008) Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes. Int J Pharm 361: 104-111.
8. Abdallah M, Sammour O, EL-Ghamry H, et al., (2013), Preparation and In-vitro Evaluation of Diclofenac Sodium Niosomal Formulatuion. IJPSR, 4(5): 1757-1765
9. Chauhan M, Sharma S, (2009), Span 60 niosomal oral suspension of fluconazole: Formulation and in vitro evaluation. JPRHC, 1: 142-156
10. Uchegbu I.F, Vyas S.P, (1998), Non ionic surfac-tant based vesicles (niosomes) in drug delivery. Int. J. Pharm., 1998, 172: 33-70.
11. Solankia A, (2008), Preparation, characteriza-tion, optimization, and stability studies of aceclo-fenac proniosomes. Iranian Journal of Pharma-ceutical Research, 7(4): 237- 246.
12. Yoshioka T, Sternberg B, Florence AT. Prepara-tion and properties of vesicles (niosomes) of sor-bitan monoesters (span 20, 40, 60, 80) and a sorbitan triester (span 85), Int J Pharma, 105 (1994) Y6.
13. Reza mozafari M, Bioactive entrapment and tar-geting using nanocarrier technologies: An intro-duction Frontiers of nanotherapy. University of Michigan, Springer, (2006)1-6.
14. Shi B, Fang C, Pei Y., Stealth, PEG-PHDCA nio-somes: effects of chain length of PEG and Particle size on niosomes surface properties, in vitro drug release, phagocytic uptake, in vivo pharmacoki-netics and antitumor activity, J. Pharm. Sci. 95 (2006) 1873–1887.
15. Azmin MN, Flourence AT., Handjani-Vila RM, Stu-art FB, Vanlerberghe G, Whittaker JS, The effect of non-ionic surfactant vescicles (niosomes) en-trapped on the absorption and distribution of methotextrate in mice, J. Pharm. Pharmacol. 37 (1985)237-242.
16. Bhaskaran. S and Panigrahi. L. Formulation and evaluation of niosomes using different nonionic surfactant. Indian Journal of pharmaceutical sci-ences. 2002, 1: 63-65.
17. Ijeoma, F, Suresh.U, Vyas.S.P. Nonionic surfactant based vesicles (niosomes) in drug delivery. In-ternational Journal of pharmaceutics, 1998, 172: 33-70.